“We are actively engaged in creating innovative drugs through open innovation to address unmet medical needs across a wide range of diseases,” said Seishi Katsumata, Executive Director, Discovery & Research of Ono. “We highly appreciate PRISM’s PepMetics® technology in PPI drug discovery, which we believe has potentials to identify and develop novel small molecule drugs for therapeutic targets that had been previously difficult to modulate with small molecules. We anticipate that the technology will further expand our development pipeline for innovative new drugs.”